Volume 8, Issue 2 (4-2026)
pbp 2026, 8(2): 199-210 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Aghdaki M, Kamkari S. Probiotics as a Therapeutic Strategy in Ovarian Cancer: Insights from Preclinical and Clinical Evidence. pbp 2026; 8 (2) :199-210
URL: http://pbp.medilam.ac.ir/article-1-392-en.html
URL: http://pbp.medilam.ac.ir/article-1-392-en.html
1- Maternal-fetal medicine Research Center, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
2- Department of Obstetrics and Gynecology, Division of Oncology Gynecology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran ,Sima.kamkari@gmail.com
2- Department of Obstetrics and Gynecology, Division of Oncology Gynecology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran ,
Abstract: (24 Views)
Introduction: Ovarian cancer remains one of the most prevalent malignancies affecting women, and current treatment strategies often have significant limitations. In recent years, probiotics have emerged as a promising adjunctive therapy alongside standard treatments. By modulating the immune system, influencing gut microbiota, and reducing inflammation, probiotics have the potential to improve outcomes for patients with ovarian cancer. This review aims to provide a comprehensive examination of the therapeutic role of probiotics in ovarian cancer management.
Methods: A literature search was performed across PubMed, Scopus, Google Scholar, and ISI Web of Science to identify studies evaluating the effects of probiotics on ovarian cancer. Evidence from in vitro, animal, and clinical studies was collected and analyzed, with a focus on probiotic effects on tumor growth, progression, and therapeutic response.
Results: Current evidence suggests that probiotics may confer multifaceted benefits in ovarian cancer management. Strains such as Lactobacillus rhamnosus (including LGG), Lactobacillus acidophilus, and Lactobacillus plantarum have demonstrated the ability to inhibit tumor-associated signaling pathways, reduce cancer cell migration and invasion, and enhance immune responses. Additionally, Bifidobacterium longum, Bifidobacterium breve, and Bifidobacterium animalis have been associated with decreased drug resistance, modulation of inflammatory responses, and restoration of gut microbiota composition. Furthermore, bacteria such as Akkermansia muciniphila and Limosilactobacillus reuteri have shown promising effects by enhancing antitumor immunity and improving the efficacy of complementary therapies. Collectively, these findings indicate that probiotics may serve as valuable adjuncts to conventional ovarian cancer treatments, potentially improving therapeutic outcomes and mitigating adverse effects. Nonetheless, further large-scale clinical trials are warranted.
Conclusion: Based on preclinical and limited clinical evidence, probiotics may serve as a safe complementary approach in ovarian cancer therapy; however, their therapeutic efficacy remains inconclusive. Consequently, they should be regarded as an adjunctive strategy rather than a standalone treatment.
Methods: A literature search was performed across PubMed, Scopus, Google Scholar, and ISI Web of Science to identify studies evaluating the effects of probiotics on ovarian cancer. Evidence from in vitro, animal, and clinical studies was collected and analyzed, with a focus on probiotic effects on tumor growth, progression, and therapeutic response.
Results: Current evidence suggests that probiotics may confer multifaceted benefits in ovarian cancer management. Strains such as Lactobacillus rhamnosus (including LGG), Lactobacillus acidophilus, and Lactobacillus plantarum have demonstrated the ability to inhibit tumor-associated signaling pathways, reduce cancer cell migration and invasion, and enhance immune responses. Additionally, Bifidobacterium longum, Bifidobacterium breve, and Bifidobacterium animalis have been associated with decreased drug resistance, modulation of inflammatory responses, and restoration of gut microbiota composition. Furthermore, bacteria such as Akkermansia muciniphila and Limosilactobacillus reuteri have shown promising effects by enhancing antitumor immunity and improving the efficacy of complementary therapies. Collectively, these findings indicate that probiotics may serve as valuable adjuncts to conventional ovarian cancer treatments, potentially improving therapeutic outcomes and mitigating adverse effects. Nonetheless, further large-scale clinical trials are warranted.
Conclusion: Based on preclinical and limited clinical evidence, probiotics may serve as a safe complementary approach in ovarian cancer therapy; however, their therapeutic efficacy remains inconclusive. Consequently, they should be regarded as an adjunctive strategy rather than a standalone treatment.
Type of Study: Review/Systemtic review |
Subject:
Pharmacological
Received: 2026/01/9 | Accepted: 2026/02/26 | Published: 2026/01/1
Received: 2026/01/9 | Accepted: 2026/02/26 | Published: 2026/01/1
References
1. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376-88. doi:10.1016/S0140-6736(13)62146-7.
2. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016;2:16061. doi:10.1038/nrdp.2016.61.
3. Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol. 2012;55(1):3-23. doi:10.1097/GRF.0b013e31824b4611.
4. Heintz AP, Hacker NF, Lagasse LD. Epidemiology and etiology of ovarian cancer: a review. Obstet Gynecol. 1985;66(1):127-35.
5. Nezhat FR, Apostol R, Nezhat C, Pejovic T. New insights in the pathophysiology of ovarian cancer and implications for screening and prevention. Am J Obstet Gynecol. 2015;213(3):262-7. doi:10.1016/j.ajog.2015.03.044.
6. Tossetta G, Inversetti A. Ovarian cancer: advances in pathophysiology and therapies. Int J Mol Sci. 2023;24(10):8930. doi:10.3390/ijms24108930.
7. Herrinton LJ, Neslund-Dudas C, Rolnick SJ, et al. Complications at the end of life in ovarian cancer. J Pain Symptom Manage. 2007;34(3):237-43. doi:10.1016/j.jpainsymman.2006.11.011.
8. Ebell MH, Culp MB, Radke TJ. A systematic review of symptoms for the diagnosis of ovarian cancer. Am J Prev Med. 2016;50(3):384-94. doi:10.1016/j.amepre.2015.09.023.
9. Della Pepa C, Tonini G, Pisano C, et al. Ovarian cancer standard of care: are there real alternatives? Chin J Cancer. 2015;34(1):17-27. doi:10.5732/cjc.014.10274.
10. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61(3):183-203. doi:10.3322/caac.20113.
11. Wang L, Wang X, Zhu X, et al. Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol Cancer. 2024;23(1):66. doi:10.1186/s12943-024-01967-3.
12. Gupta V, Garg R. Probiotics. Indian J Med Microbiol. 2009;27(3):202-9.
13. Wu LY, Yang TH, Ou YC, Lin H. The role of probiotics in women's health: an update narrative review. Taiwan J Obstet Gynecol. 2024;63(1):29-36. doi:10.1016/j.tjog.2023.09.018.
14. Maysa AN. Stress and probiotics in ovarian cancer [dissertation]. Brighton: University of Brighton; 2023.
15. Zhou X, Hu G, Luo Z, et al. Probiotics alleviate paraneoplastic thrombocythemia of ovarian cancer: a randomized placebo-controlled trial. J Funct Foods. 2024;119:106316. doi:10.1016/j.jff.2024.106316.
16. Alipour S, Abdolalizadeh MM, Amirkhiz MB, Abdolalizadeh J. Effects of Lactobacillus rhamnosus on SKT-PI3K signaling pathways and PTEN gene expression in CAOV-4 ovarian cancer cells. Cancer Plus. 2023;5(4):1968.
17. Sipos A, Ujlaki G, Mikó E, et al. The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and bacterial metabolite signaling. Mol Med. 2021;27(1):33. doi:10.1186/s10020-021-00295-2.
18. 18. Hamade DF, Epperly MW, Fisher R, et al. Genetically engineered probiotic Limosilactobacillus reuteri releasing IL-22 modifies the tumor microenvironment in ovarian cancer. Cancers (Basel). 2024;16(3):474. doi:10.3390/cancers16030474.
19. Blanco JR, Del Campo R, Avendaño-Ortiz J, et al. The role of microbiota in ovarian cancer: implications for treatment response. Cells. 2025;14(22):1813. doi:10.3390/cells14221813.
20. Mitra A, Gultekin M, Ellis LB, et al. Genital tract microbiota and use of pre/probiotics in gynaecological cancer prevention. Lancet Microbe. 2024;5(3):e291-300. doi:10.1016/S2666-5247(23)00257-4.
21. Pourmollaei S, Farshbaf-Khalili A, Barzegari A, et al. Anticancer effect of Enterococcus faecium isolated from vaginal fluid on ovarian cancer cells. Iran Biomed J. 2023;27(4):205. doi:10.61186/ibj.3846.
22. Chen C, Deng C, Li Y, et al. Machine learning-derived diagnostic model of epithelial ovarian cancer based on gut microbiome signatures. J Transl Med. 2025;23(1):319. doi:10.1186/s12967-025-06339-z.
23. Fan YL, Jin JX, Zhu J, et al. Extracellular vesicles of Bifidobacterium longum reverse carboplatin resistance in ovarian cancer cells. Kaohsiung J Med Sci. 2024;40(6):530-41. doi:10.1002/kjm2.12837.
24. Zhou B, Sun C, Huang J, et al. Biodiversity composition of microbiome in ovarian carcinoma patients. Sci Rep. 2019;9:1691.
25. Xie B, Zhou X, Luo C, et al. Reversal of platinum-based chemotherapy resistance by naringin through gut microbiota modulation. J Cancer. 2024;15(13):4430. doi:10.7150/jca.96448.
26. Hamade DF, Espinal A, Yu J, et al. Lactobacillus reuteri releasing IL-22 facilitates intestinal radioprotection. Radiat Res. 2022;198(1):89-105. doi:10.1667/RADE-21-00224.1.
27. Capozzi VA, Incognito GG, Scarpelli E, et al. Relationship between ovarian cancer and genital microbiota: a systematic review and meta-analysis. J Pers Med. 2024;14(4):351. doi:10.3390/jpm14040351.
28. Zhan X, Zuo Q, Huang G, et al. Tripterygium glycosides sensitize cisplatin by modulating gut microbiota. Front Cell Infect Microbiol. 2023;13:1236272. doi:10.3389/fcimb.2023.1236272.
29. Tong J, Zhang X, Fan Y, et al. Changes of intestinal microbiota in ovarian cancer patients after surgery and chemotherapy. Cancer Manag Res. 2020;12:8125-35. doi:10.2147/CMAR.S265205.
30. Lin C, Zeng Z, Lin Y, et al. Naringenin suppresses epithelial ovarian cancer by modulating gut microbiota. Phytomedicine. 2022;106:154401. doi:10.1016/j.phymed.2022.154401.
31. Okazawa-Sakai M, Sakai SA, Hyodo I, et al. Gut microbiome associated with PARP inhibitor efficacy in ovarian cancer. J Gynecol Oncol. 2025;36(3):e38. doi:10.3802/jgo.2025.36.e38.
32. Chirakkara SP, Abraham A. Exopolysaccharide from Bacillus velezensis triggers apoptosis in ovarian cancer cells. J Appl Pharm Sci. 2023;13(6):154-64. doi:10.7324/JAPS.2023.110355.
33. Wang Z, Qin X, Hu D, et al. Akkermansia supplementation reverses tumor-promoting effects of FMT in ovarian cancer. Cell Rep. 2022;41(13):111890. doi:10.1016/j.celrep.2022.111890.
34. Jacobson D, Moore K, Gunderson C, et al. Shifts in gut and vaginal microbiomes associated with recurrence time in ovarian cancer. PeerJ. 2021;9:e11574. doi:10.7717/peerj.11574.
35. Dominique GM, Hammond C, Stack MS. The gut microbiome in aging and ovarian cancer. Aging Cancer. 2024;5(1-2):14-34. doi:10.1002/aac2.12071.
36. D’Amico F, Perrone AM, Rampelli S, et al. Gut microbiota dynamics during chemotherapy in ovarian cancer. Cancers (Basel). 2021;13(16):3999. doi:10.3390/cancers13163999.
37. Huang Q, Wei X, Li W, et al. Propionibacterium acnes promotes ovarian cancer via hedgehog signaling. Cancers (Basel). 2022;14(21):5178. doi:10.3390/cancers14215178.
38. Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, Gil A. Mechanisms of action of probiotics. Adv Nutr. 2019;10(Suppl 1):S49-66. doi:10.1093/advances/nmy063.
39. Dos Reis SA, da Conceição LL, Siqueira NP, et al. Mechanisms of probiotic actions in colorectal cancer prevention. Nutr Res. 2017;37:1-9. doi:10.1016/j.nutres.2016.11.009.
40. Borase H, Dwivedi MK, Krishnamurthy R, Patil S. Probiotics: health safety considerations. In: Probiotics in the Prevention and Management of Human Diseases. Academic Press; 2022. p.449-463.
41. Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. 2015;60(Suppl 2):S129-34. doi:10.1093/cid/civ085.
42. Didari T, Solki S, Mozaffari S, Nikfar S, Abdollahi M. Safety of probiotics: a systematic review. Expert Opin Drug Saf. 2014;13(2):227-39. doi:10.1517/14740338.2014.872627.
43. Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. 2015;60(Suppl 2):S129-34. doi:10.1093/cid/civ085.
44. Didari T, Solki S, Mozaffari S, Nikfar S, Abdollahi M. A systematic review of the safety of probiotics. Expert Opin Drug Saf. 2014;13(2):227-39. doi:10.1517/14740338.2014.872627.
45. Najib FS, Izanloo E, Aghdaki M, Khansalar S, Fattahi MJ, Oveisi Z, Haghshenas MR. Stromal cell-derived factor-1 genetic variation at locus 801 in patients with endometrial cancer. Middle East Journal of Cancer. 2025 Apr 1;16(2):181-8.
46. Faraji A, Aghdaki M, Hessami K, Hosseinkhani A, Roozmeh S, Asadi N, Vafaei H, Kasraeian M, Bagheri R, Bazrafshan K, Foroughinia L. Episiotomy wound healing by Commiphora myrrha (Nees) Engl. and Boswellia carteri Birdw. in primiparous women: a randomized controlled trial. Journal of Ethnopharmacology. 2021 Jan 10;264:113396. doi: 10.1016/j.jep.2020.113396
47. Shiravani Z, Najib FS, Kamkari S, Bahrami S. Survival rates and prognostic factors among patients with endometrial cancer. International Journal of Cancer Management. 2025;18(18):e164445. doi: https://doi.org/10.5812/ijcm-144897
48. Salehi AM, Shahbazi F, Garavand R, Kamkari S, Jenabi E. Global socioeconomic inequalities in breast, cervical, ovarian, and uterine cancers incidence, mortality, and disability-adjusted life year rates: a relative concentration index analysis. BMC Women's Health. 2025 Sep 25;25(1):433. doi: 10.1186/s12905-025-03961-3
49. Shahbazi R, Zamanibonab M, Kamkari S, Mohammadi Y, Rastgoy Haghi A. The study of the effect of the COVID-19 pandemic on the diagnosis of patients afflicted with gynecologic cancer. Journal of Obstetrics, Gynecology and Cancer Research. 2024 May 15;9(3):270-5. doi: https://doi.org/10.30699/jogcr.9.3.270
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |